Addressing Gaps in Care for Non-Small Cell Lung Cancer

EP: 1.Treatment Approaches for Early-Stage Lung Cancer

EP: 2.Driving Precision Medicine Through Molecular Testing in NSCLC

EP: 3.Neoadjuvant/Perioperative Immunotherapy in NSCLC

EP: 4.Referral of Early-Stage NSCLC to Multidisciplinary Teams

EP: 5.Neoadjuvant, Adjuvant, and Perioperative Options in NSCLC

EP: 6.Updates in CheckMate-816 From ESMO 2023

EP: 7.AEGEAN Trial: Perioperative Approach in NSCLC

EP: 8.Latest From the NEOTORCH Trial & KEYNOTE-671 Trial

EP: 9.CheckMate-77T Trial Results From ESMO 2023

EP: 10.Treatment Decision Making by Stage for Resectable NSCLC

EP: 11.The Emerging Role of ctDNA in NSCLC Management

Now Viewing

EP: 12.Addressing Gaps in Care for Non-Small Cell Lung Cancer

This is a video synopsis/summary of a Precision Medicine featuring Patrick Forde, MBBCh, and Tina Cascone, MD, PhD.

Forde and Cascone discuss the unmet needs and future directions in the preoperative treatment of NSCLC. Despite the recent advances in this setting, there remain uncertainties regarding which patients will benefit from neoadjuvant, adjuvant, or perioperative approaches. It is unclear which patients without a pathologic complete response (pCR) should continue treatment and whether those with a pCR should continue therapy as well.

Tailoring treatment strategies based on subgroups and biomarkers is a critical unmet need. Real-time informative factors, such as PD-L1 expression, ctDNA clearance, staging, and other markers, could help determine which approach is most suitable for individual patients. The next generation of trials and preclinical and translational work should aim to address these questions.

As observed in advanced disease, the segmentation of patient populations and selection based on tumor biomarkers and other elements may allow for more personalized treatment in the early-stage setting. Rather than treating all patients with the same 1-year or 9-week treatment, tailoring therapy more specifically is a goal for the future. With the rapid progress made in recent years, there is hope for continued advancements in the field.

Video synopsis is AI-generated and reviewed by Targeted Oncology™ editorial staff.